Literature DB >> 2556073

Molecular analysis of the inhibitory effect of phosphorylated ribavirin on the vesicular stomatitis virus in vitro polymerase reaction.

R Fernandez-Larsson1, K O'Connell, E Koumans, J L Patterson.   

Abstract

The effect of phosphorylated ribavirin on the vesicular stomatitis virus in vitro transcription reaction was examined. Analysis of the kinetics observed when the concentrations of nucleoside triphosphates were varied was performed with vesicular stomatitis virus wild-type standard virions. Double-reciprocal and Eadie-Hofstee plots showed competitive inhibition with all natural nucleoside triphosphates when both ribavirin diphosphate (RDP) and ribavirin triphosphate (RTP) were used. The Km values for ATP obtained for the wild-type polymerase were similar to those reported previously. To further characterize the observed inhibition kinetics, in vitro transcription products synthesized in the presence or absence of RDP and RTP were purified by CsCl centrifugation and were primer extended with oligonucleotides specific for either positive-sense leader or nucleocapsid mRNA transcripts. The ratios of leader to nucleocapsid mRNA were measured from primer-extended in vitro transcription products. It was found that the addition of RDP or RTP did not significantly change the in vitro ratio, suggesting that the polymerase is blocked before it enters the 3' end of the template.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2556073      PMCID: PMC172735          DOI: 10.1128/AAC.33.10.1668

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Plus and minus strand leader RNAs in negative strand virus-infected cells.

Authors:  M Leppert; L Rittenhouse; J Perrault; D F Summers; D Kolakofsky
Journal:  Cell       Date:  1979-11       Impact factor: 41.582

2.  The broad spectrum antiviral agent ribavirin inhibits capping of mRNA.

Authors:  B B Goswami; E Borek; O K Sharma; J Fujitaki; R A Smith
Journal:  Biochem Biophys Res Commun       Date:  1979-08-13       Impact factor: 3.575

3.  Initiation of RNA synthesis in vitro by vesicular stomatitis virus. Role of ATP.

Authors:  D Testa; A K Banerjee
Journal:  J Biol Chem       Date:  1979-03-25       Impact factor: 5.157

4.  Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate.

Authors:  B Eriksson; E Helgstrand; N G Johansson; A Larsson; A Misiorny; J O Norén; L Philipson; K Stenberg; G Stening; S Stridh; B Oberg
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

5.  Synthesis and antiviral acticity of some phosphates of the broad-spectrum antiviral nucleoside, 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin).

Authors:  L B Allen; K H Boswell; T A Khwaja; R B Meyer; R W Sidwell; J T Witkowski; L F Christensen; R K Robins
Journal:  J Med Chem       Date:  1978-08       Impact factor: 7.446

6.  Inhibitors of IMP dehydrogenase prevent sindbis virus replication and reduce GTP levels in Aedes albopictus cells.

Authors:  F Malinoski; V Stollar
Journal:  Virology       Date:  1981-04-30       Impact factor: 3.616

7.  Effect of the beta-gamma phosphate bond of ATP on synthesis of leader RNA and mRNAs of vesicular stomatitis virus.

Authors:  T L Green; S U Emerson
Journal:  J Virol       Date:  1984-04       Impact factor: 5.103

8.  Statistical methods to distinguish competitive, noncompetitive, and uncompetitive enzyme inhibitors.

Authors:  T Spector; G Hajian
Journal:  Anal Biochem       Date:  1981-08       Impact factor: 3.365

9.  Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent.

Authors:  D G Streeter; J T Witkowski; G P Khare; R W Sidwell; R J Bauer; R K Robins; L N Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1973-04       Impact factor: 11.205

10.  Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription.

Authors:  L E Iverson; J K Rose
Journal:  Cell       Date:  1981-02       Impact factor: 41.582

View more
  19 in total

1.  Mechanism of action of ribavirin in the treatment of chronic hepatitis C.

Authors:  Helen S Te; Glenn Randall; Donald M Jensen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

Review 2.  In vitro capping and transcription of rhabdoviruses.

Authors:  Tomoaki Ogino
Journal:  Methods       Date:  2012-06-08       Impact factor: 3.608

Review 3.  The application and mechanism of action of ribavirin in therapy of hepatitis C.

Authors:  Emmanuel Thomas; Marc G Ghany; T Jake Liang
Journal:  Antivir Chem Chemother       Date:  2012-09-25

4.  Mechanism of La Crosse virus inhibition by ribavirin.

Authors:  L F Cassidy; J L Patterson
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

Review 5.  Polymerases of paramyxoviruses and pneumoviruses.

Authors:  Rachel Fearns; Richard K Plemper
Journal:  Virus Res       Date:  2017-01-16       Impact factor: 3.303

6.  Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase.

Authors:  Yanjie Sun; Dong-Hoon Chung; Yong-Kyu Chu; Colleen B Jonsson; William B Parker
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

7.  Concentration of 2'C-methyladenosine triphosphate by Leishmania guyanensis enables specific inhibition of Leishmania RNA virus 1 via its RNA polymerase.

Authors:  John I Robinson; Stephen M Beverley
Journal:  J Biol Chem       Date:  2018-03-06       Impact factor: 5.157

8.  Inhibitory effect of a nucleotide analog on infectious salmon anemia virus infection.

Authors:  Andrea Rivas-Aravena; Eva Vallejos-Vidal; Marcelo Cortez-San Martin; Felipe Reyes-Lopez; Mario Tello; Patricia Mora; Ana María Sandino; Eugenio Spencer
Journal:  J Virol       Date:  2011-06-08       Impact factor: 5.103

9.  High-throughput screening of a 100,000-compound library for inhibitors of influenza A virus (H3N2).

Authors:  William E Severson; Michael McDowell; Subramaniam Ananthan; Dong-Hoon Chung; Lynn Rasmussen; Melinda I Sosa; E Lucile White; James Noah; Colleen B Jonsson
Journal:  J Biomol Screen       Date:  2008-09-23

10.  (S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection.

Authors:  Blake P Moore; Dong Hoon Chung; Daljit S Matharu; Jennifer E Golden; Clinton Maddox; Lynn Rasmussen; James W Noah; Melinda I Sosa; Subramaniam Ananthan; Nichole A Tower; E Lucile White; Fuli Jia; Thomas E Prisinzano; Jeffrey Aubé; Colleen B Jonsson; William E Severson
Journal:  J Med Chem       Date:  2012-10-16       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.